Earlier Today GSK's Phase 1/2 Proof-Of-Concept Study Of GSK3943104 Did Not Meet The Study's Primary Efficacy Objective, Hence It Will Not Progress To Phase 3 Studies
Earlier Today GSK's Phase 1/2 Proof-Of-Concept Study Of GSK3943104 Did Not Meet The Study's Primary Efficacy Objective, Hence It Will Not Progress To Phase 3 Studies
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.